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OBJECTIVE—Activation of the alternative pathway of the
complement system, in which factor H (fH; complement fH
[CFH]) is a key regulatory component, has been suggested as a
link between obesity and metabolic disorders. Our objective was
to study the associations between circulating and adipose tissue
gene expressions of CFH and complement factor B (fB; CFB)
with obesity and insulin resistance.
RESEARCH DESIGN AND METHODS—Circulating fH and fB
were determined by enzyme-linked immunosorbent assay in 398
subjects. CFH and CFB gene expressions were evaluated in 76
adipose tissue samples, in isolated adipocytes, and in stromovas-
cular cells (SVC) (n  13). The effects of weight loss and
rosiglitazone were investigated in independent cohorts.
RESULTS—Both circulating fH and fB were associated posi-
tively with BMI, waist circumference, triglycerides, and inﬂam-
matory parameters and negatively with insulin sensitivity and
HDL cholesterol. For the ﬁrst time, CFH gene expression was
detected in human adipose tissue (signiﬁcantly increased in
subcutaneous compared with omental fat). CFH gene expression
in omental fat was signiﬁcantly associated with insulin resis-
tance. In contrast, CFB gene expression was signiﬁcantly in-
creased in omental fat but also in association with fasting
glucose and triglycerides. The SVC fraction was responsible for
these differences, although isolated adipocytes also expressed fB
and fH at low levels. Both weight loss and rosiglitazone led to
signiﬁcantly decreased circulating fB and fH levels.
CONCLUSIONS—Increased circulating fH and fB concentra-
tions in subjects with altered glucose tolerance could reﬂect
increased SVC-induced activation of the alternative pathway of
complement in omental adipose tissue linked to insulin resis-
tance and metabolic disturbances. Diabetes 59:200–209, 2010
O
besity is closely associated with a cluster of
metabolic diseases, such as dyslipidemia, hy-
pertension, insulin resistance, type 2 diabetes,
and atherosclerosis (1). Adipose tissue is well
known for its essential role as an energy storage depot and
for secreting adipokines that inﬂuence sites as diverse as
brain, liver, muscle, -cells, gonads, lymphoid organs, and
systemic vasculature (2,3). Expression analysis of macro-
phage and nonmacrophage cell populations isolated from
adipose tissue demonstrates that adipose tissue macro-
phages are responsible for most of the proinﬂammatory
cytokines (4). In recent years, it has become evident that
alterations in the function of the innate immune system are
intrinsically linked to metabolic pathways in humans (5–8).
The complement system is a major component of the
innate immune system, defending the host against patho-
gens, coordinating various events during inﬂammation,
and bridging innate and adaptive immune responses. Com-
plement deﬁciency and abnormalities in the regulation of
the complement system lead to increased susceptibility to
infection and chronic inﬂammatory diseases (9,10,11).
Factor H (fH) is a relatively abundant plasma glycopro-
tein that is essential to maintain complement homeostasis
and to restrict the action of complement to activating
surfaces. fH acts as a cofactor for factor I–mediated
cleavage of C3b (the active fragment of the third compo-
nent of complement C3), accelerates the dissociation of
the alternative pathway C3 convertases (a bimolecular
enzymatic complex formed by active fragments of C3 and
factor B [fB]), and competes with fB for binding to C3b. fH
regulates complement both in ﬂuid phase and on cellular
surfaces (12–16).
It has been suggested that activation of the alternative
pathway of the complement system could be a link be-
tween obesity and metabolic disorders (17–21). Moreover,
fB and factor D (fD, adipsin) are produced by adipose
tissue where they likely inﬂuence formation of the alter-
native pathway component C3 convertase and the produc-
tion of the anaphylatoxin C3a and its carboxypeptidase
B-anaphylatoxic–inactivated derivative C3adesArg (acyla-
tion-stimulating protein [ASP]). Both ASP/C3adesArg and
C3a interact with the receptor C5L2 to effectively stimulate
triglyceride synthesis in cultured adipocytes (22). C3
knockout (C3KO) mice are obligatorily ASP deﬁcient and
present lipid abnormalities (23). In humans, ASP levels are
increased in obesity, type 2 diabetes, and in individuals at
risk of arterial disease, including those with hypertension,
type 2 diabetes, dyslipidemia, and coronary artery disease,
whereas exercise or weight loss decreases ASP levels
(24,25). These data suggest a relationship between these
conditions and activation of the alternative pathway of
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creased C3 concentration and decreased insulin action
(26,27). Levels of C3 and fB were higher in subjects with
insulin resistance and other features of the metabolic
syndrome (28,29).
Given these interactions among activation of the alter-
native pathway of complement, metabolic disturbances,
and a chronic low-level inﬂammatory state, we designed
experiments to study the associations among circulating
fH, fB, insulin resistance, lipid parameters, and inﬂamma-
tory markers. We found that circulating fH and fB are
strongly associated with obesity. For that reason, we also
studied whether adipose tissue could constitute a source
of circulating fH and fB.
RESEARCH DESIGN AND METHODS
For this study 398 Caucasian men were recruited, and 259 subjects were
randomly localized from a census and were invited to participate. The
participation rate was 71%. A 75-g oral glucose tolerance test (OGTT),
according to the American Diabetes Association criteria, was performed in all
subjects. All subjects with normal glucose tolerance (NGT) (n  140) had fasting
plasma glucose 7.0 mmol/l and 2-h postload plasma glucose 7.8 mmol/l after
a 75-g OGTT. Glucose intolerance was diagnosed in 83 subjects according to the
American Diabetes Association Criteria (postload glucose 7.8–11.1 mmol/l).
Previously unknown type 2 diabetes was diagnosed in 36 additional subjects
(postload glucose 11.1 mmol/l/l). Subjects with glucose intolerance and type 2
diabetes were grouped as altered glucose tolerance (AGT).
Inclusion criteria were 1) BMI 40 kg/m
2, 2) absence of systemic disease,
and 3) absence of infection within the previous month. None of the control
subjects were under medication or had evidence of metabolic disease other
than obesity. Liver disease and thyroid dysfunction were speciﬁcally excluded
by biochemical workup.
In order to increase the statistical power of the group of patients with type
2 diabetes, 139 patients were prospectively recruited from diabetes outpatient
clinics on the basis of stable metabolic control in the previous 6 months,
deﬁned by stable A1C values. Data from these patients were merged with
those from the recently diagnosed type 2 diabetic patients. Exclusion criteria
for these patients included the following: 1) clinically signiﬁcant hepatic,
neurological, endocrinologic, or other major systemic disease including
malignancy; 2) history or current clinical evidence of hemochromatosis; 3)
history of drug or alcohol abuse, deﬁned as 80 g/day in men and 40 g/day
in women; 4) elevated serum creatinine concentration; 5) acute major
cardiovascular event in the previous 6 months; 6) acute illnesses and current
evidence of acute or chronic inﬂammatory or infective diseases; and 7) mental
illness rendering the subjects unable to understand the nature, scope, and
possible consequences of the study. Pharmacological treatment for these
patients was insulin, 31 patients; metformin, 37 patients; sulfonylureas, 16
patients; statins, 34 patients; ﬁbrates, 9 patients; blood pressure–lowering
agents, 38 patients; aspirin, 42 patients; and allopurinol, 3 patients. All subjects
gave written informed consent after the purpose of the study was explained to
them. The institutional review board approved the protocol.
Subjects were studied after at least 10 h of fasting. BMI was calculated as
weight in kilograms divided by height in meters squared. Blood pressure was
measured in the supine position on the right arm after a 10-min rest; a
standard sphygmomanometer of appropriate cuff size was used, and the ﬁrst
and ﬁfth phases were recorded. Values used in the analysis are the average of
three readings taken at 5-min intervals.
Insulin sensitivity was measured using the frequently sampled intravenous
glucose tolerance test on a different day in those subjects who agreed (n 
147). In brief, basal blood samples were drawn at 15 and 5 min, after which
glucose (300 mg/kg body wt) was injected over 1 min starting at time 0. At 20
min, regular insulin (0.03 units/kg actrapid; Novo Nordisk, Denmark) was
injected as a bolus. Additional samples were obtained from a contralateral
antecubital vein at times 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 20, 22, 23, 24, 25,
27, 30, 40, 50, 60,70, 80, 90, 100, 120, 140, 160, and 180 min. Samples were
rapidly collected via a three-way stopcock connected to a butterﬂy needle.
Data from the frequently sampled intravenous glucose tolerance test were
submitted to computer programs that calculate the characteristic metabolic
parameters by ﬁtting glucose and insulin to the minimal model that describes
the time course of glucose and insulin concentrations. The glucose disappear-
ance model, by accounting for the effect of insulin and glucose on glucose
disappearance, provides the parameters for the insulin sensitivity index (10
4
min  U
1  ml
1), or a measure of the effect of insulin concentrations above
the basal level to enhance glucose disappearance. The estimation of model
parameters was performed according to the minimal model (MINMOD)
analysis computer program (30).
Insulin resistance was also measured by the homeostasis model assess-
ment of insulin resistance (HOMA-IR). HOMA-IR correlates well with insulin
sensitivity derived from the glucose clamp technique (r  0.82; P  0.0001)
(31). In the weight loss study, an indirect measure of insulin sensitivity was
calculated from the fasting plasma glucose and insulin concentrations by
using the quantitative insulin sensitivity check index (QUICKI) (32).
Complement fH and fB expression in adipose tissue, stromal vascular
fraction, and isolated adipocytes. A group of 76 adipose tissue samples (38
omental and 38 subcutaneous depots) from participants (19 men and 19
women, aged 43.7  9.9 years, mean BMI 43.9  8.6 kg/m
2, fasting glucose
110.6  28.9 mg/dl, log fasting insulin 1.12  0.36 mU/l, total cholesterol
200.1  40.77 mg/dl, HDL cholesterol 46.2  18.5 mg/dl, LDL cholesterol
128.7  33.3 mg/dl, and log fasting triglycerides 2  0.2 mg/dl) who were
recruited at the Endocrinology Department at the University Clinic of Navarra
(Pamplona, Spain) and at the Endocrinology Service of the Hospital Univer-
sitari Dr. Josep Trueta (Girona, Spain) were analyzed. All subjects were of
Caucasian descent and reported that their body weight had been stable for 3
months before the study. Liver and renal diseases were speciﬁcally excluded
by biochemical workup. All subjects gave written informed consent after the
purpose of the study was explained to them.
Adipose tissue samples were obtained from subcutaneous and omental
depots during elective surgical procedures (cholecystectomy, surgery of
abdominal hernia, and gastric bypass surgery). Both subcutaneous and
omental fat were obtained from the abdomen following standard procedures.
To analyze adipose tissue gene expression, tissues were washed, fragmented,
and immediately ﬂash frozen in liquid nitrogen before being stored at 80°C.
To perform the isolation of adipocyte and stromal vascular fraction (SVF),
tissues were washed three to four times with PBS and suspended in an equal
volume of PBS supplemented with 1% bovine serum albumin (BSA) and 0.1%
collagenase type I prewarmed to 37°C. The tissue was placed in a shaking water
bath at 37°C with continuous agitation for 60 min and centrifuged for 5 min at
300–500 g at room temperature. The supernatant, containing mature adipocytes,
was recollected. The pellet was identiﬁed as the SVF cell. The adipose tissue
fractionation was performed from seven omental and six subcutaneous depots.
RNA was prepared from these samples using RNeasy Lipid Tissue Mini Kit
(QIAgen). The integrity of each RNA sample was checked by Agilent Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). Total RNA was quantiﬁed by
means of spectrophotometer (GeneQuant, GE Health Care, Piscataway NJ)
reverse transcribed to cDNA using High-Capacity cDNA Archive Kit (Applied
Biosystems, Darmstadt, Germany) according to the manufacturer’s protocol.
Gene expression was assessed by real-time PCR using an ABI Prism 7000
TABLE 1
Clinical characteristics of subjects in the cross-sectional study
NGT AGT P
n 140 258 —
Age (years) 48.8  11.2 55.5  12.7 0.0001
BMI (kg/m
2) 26.7  3.7 28.9  5.2 0.0001
Waist-to-hip ratio 0.92  0.06 0.97  0.07 0.0001
Systolic blood pressure
(mmHg) 122.9  14.6 139.8  20.3 0.0001
Diastolic blood pressure
(mmHg) 77.9  10.7 81.8  10.2 0.001
Fasting glucose (mg/dl) 92.15  8.05 160.3  82.9 0.0001
A1C (%) 4.7  0.32 7.01  1.8 0.0001
Total cholesterol (mg/dl) 204.05  35 205.5  37.9 0.7
HDL cholesterol (mg/dl) 53.8  13.02 48.3  12.4 0.0001
LDL cholesterol (mg/dl) 132.5  31.6 120.2  38.9 0.002
Log 10 fasting
triglycerides (mg/dl) 1.9  0.24 2.2  0.27 0.0001
sTNFR2 (ng/ml) 6.49  3.5 8.02  5.25 0.001
LBP (g/ml) 19.7  13.9 44.2  29.4 0.0001
Log insulin sensitivity
index* 0.58  0.2 0.34  0.18 0.0001
CFH (g/ml) 175.2  53.4 195.4  63.5 0.01
CFB (g/ml) 231.95  58.8 285.9  90.5 0.0001
Data are means  SD unless otherwise indicated. *Insulin sensitivity
was measured in 147 subjects (83 subjects with NGT and 64 subjects
with AGT) using the frequently sampled intravenous glucose toler-
ance test.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 201Sequence Detection System (Applied Biosystems, Darmstadt, Germany), using
TaqMan technology suitable for relative genetic expression quantiﬁcation.
The commercially available and prevalidated TaqMan primer/probe sets
used were as follows: endogenous control PPIA (4333763, cyclophilin A) and
target genes complement fH (CFH) (Hs00164830_m1) and complement fB
(CFB) (Hs00156060_m1). The RT-PCR TaqMan reaction was performed in a
ﬁnal volume of 25 l. The cycle program consisted of an initial denaturing of
10 min at 95°C then 40 cycles of 15-s denaturizing phase at 95°C and a 1-min
annealing and extension phase at 60°C. A threshold cycle (Ct value) was
obtained for each ampliﬁcation curve, and a Ct value was ﬁrst calculated by
subtracting the Ct value for human Cyclophilin A (PPIA) RNA from the Ct
value for each sample. Fold changes compared with the endogenous control
were then determined by calculating 2
Ct, so gene expression results are
expressed as an expression ratio relative to PPIA gene expression according
to manufacturers’ guidelines.
Study of the effects of weight loss. We recruited 42 Caucasian obese
volunteers (22 women, 20 men, and age range 27–70 years) attending the
Endocrinology Department at the University Clinic of Navarra. Patients
underwent a clinical assessment including medical history, physical examina-
tion, body composition analysis, and comorbidity evaluation as well as
nutritional interviews performed by a multidisciplinary consultation team. All
subjects were nonsmokers. Patients with signs of infection were excluded.
Obese patients were not receiving statins or antidiabetes medication.
Weight loss was achieved by prescription of a diet providing a daily energy
deﬁcit of 500–1,000 kcal/day calculated from the determination of the resting
energy expenditure through indirect calorimetry (Vmax29; SensorMedics,
Yorba Linda, CA) and multiplication by 1.4, indicated for sedentary individuals
to obtain the patients’ total energy expenditure during 4 months. This
hypocaloric regimen allows a safe and steady weight loss of 0.5–1.0 kg/week
when followed and supplied 30, 54, and 16% of energy requirements in the
form of fat, carbohydrates, and protein, respectively. In this study body weight
was measured with a digital scale to the nearest 0.1 kg, and height was
measured to the nearest 0.1 cm with a Holtain stadiometer (Holtain, Crymych,
U.K.). The institutional review board of the participant institutions approved
the protocol, so we certify that all applicable institutional regulations con-
cerning the ethical use of information and samples from human volunteers
were followed during this research.
Effects of rosiglitazone in circulating fB and fH. We conducted a
parallel-group randomized and controlled trial to evaluate the effects of
rosiglitazone on endothelial function in patients with coronary artery disease
and pre-diabetes over a 6-month period. Consecutive patients of either sex (5
women, 15 men, and age range 37–72 years) referred to the University of
Leipzig Heart Center, Germany, were invited to participate if they displayed
impaired fasting glucose (6.0 and 7.0 mmol/l with A1C 6%) or impaired
glucose tolerance (7.8 and 11.1 mmol/l 2 h after oral intake of 75 g glucose)
and angiographic evidence of coronary artery disease (50% stenosis diame-
ter in at least one major epicardial artery).
Exclusion criteria included diabetes type 1 or 2, preexisting antidiabetes
medication, unstable angina, indication for coronary bypass surgery, signiﬁ-
cant left main disease, myocardial infarction within preceding 3 months,
ejection fraction 40%, signiﬁcant heart valve disease, severe metabolic
disorders, severe disorders in lipoprotein metabolism, thyroid disorders,
alcohol or drug abuse, pregnancy, and participation in another trial.
Eligible patients were randomly assigned to one of two treatment groups
r=0.21, p<0.0001, n= 398 r= -0.27, p<0.0001, n= 147
r= -0.26, p<0.0001, n= 147 r=0.22, p<0.0001, n= 398
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FIG. 1. Linear relationships between CFH and CFB with BMI and log insulin sensitivity index (derived from the minimal model).
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202 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgfor 6 months: group A received 8 mg rosiglitazone daily (Avandia; GlaxoSmith-
Kline, London, U.K.) (n  12), group B served as a control group (n  8).
Patients who served as control subjects did not receive rosiglitazone. Ran-
domization was performed by drawing sealed opaque envelopes. At day 1
(baseline) after 4 weeks and 6 months, patients were clinically examined,
endothelial function was assessed, and blood samples were obtained. The
protocol was approved by the local ethics committee. All subjects gave
written informed consent before enrollment.
Analytical methods. Serum glucose concentrations were measured in dupli-
cate by the glucose oxidase method using a Beckman Glucose Analyzer II
(Beckman Instruments, Brea, CA). A1C was measured by the high-perfor-
mance liquid chromatography method (Bio-Rad, Muenchen, Germany, and
autoanalyzer Jokoh HS-10, respectively). Intra-assay and interassay coefﬁ-
cients of variation (CVs) were 4% for all tests. HDL cholesterol was
quantiﬁed after precipitation with polyethylene glycol at room temperature.
Total serum triglycerides were measured through the reaction of glycerol/
phosphate/oxidase and peroxidase. Serum insulin was measured in duplicate
in the same centralized laboratory by a monoclonal immunoradiometric assay
(Medgenix Diagnostics, Fleunes, Belgium). The intra-assay CV was 5.2% at a
concentration of 10 mU/l and 3.4% at 130 mU/l. The interassay CVs were 6.9
and 4.5% at 14 and 89 mU/l, respectively.
Serum-soluble tumor necrosis factor-	 receptor-2 (sTNFR2) concentration
was measured by sTNF-RII EASIATM ELISA kit (Biosource Europe, Belgium);
serum lipopolysaccharide binding protein (LBP) levels were measured by
Human LBP ELISA kit (HyCult biotechnology, PB Uden, the Netherlands).
Intra- and interassay coefﬁcients of variation for all these determinations were
between 5–10%.
Complement ELISA. FH and fB levels were measured by a sandwich ELISA
method. In brief, 96-well microtiter plates were coated overnight with a
polyclonal rabbit 	-human fH or fB antibodies (capture antibody) diluted in
0.1 mol/l NaHCO3 pH9.5 buffer at 4°C. After blocking for1ha troom
temperature with 50 mmol/l Tris pH 7.4, 150 mmol/l NaCl 0.2% Tween 20, and
1% BSA, samples were added and incubated for1ha troom temperature.
Appropriate dilutions of puriﬁed human fH and fB were used to prepare a
standard curve. Two in-house mouse monoclonals 	-human fH (35H9) and
	-human fB (JC1) were used as detecting antibodies. These monoclonal
antibodies are well-characterized reagents that have been used extensively in
ELISA and afﬁnity-chromatography methodologies to measure levels of fH and
fB and to purify these proteins from human plasma (33,34). After incubation
with rabbit 	-mouse Ig antibodies conjugated to horseradish peroxidase,
(DAKO, Denmark) plates were developed with o-phenyl-diamine (DAKO,
Denmark) and absorbance measured at 492 nm. Intra- and interassay CVs for
all these determinations were 2–8%.
Statistical methods. Statistical analyses were performed using SPSS 12.0
software. Unless otherwise stated, descriptive results of continuous variables
are expressed as means  SD for Gaussian variables. Parameters that did not
fulﬁll normal distribution were logarithmically transformed to improve sym-
metry for subsequent analyses. The relation between variables was analyzed
by simple correlation (Pearson test) and multiple regression analyses. Un-
paired and paired t tests were used to compare NGT and AGT subjects and the
effects of weight loss or rosiglitazone and the comparison of fH and fB gene
expression between subcutaneous and omental adipose tissue, respectively.
Levels of statistical signiﬁcance were set at P  0.05.
RESULTS
Circulating fB and fH concentration analysis. The
metabolic characteristics of both groups are shown in
Table 1. Circulating fH concentrations were signiﬁcantly
associated with circulating fB concentrations (r  0.65;
P  0.0001). Circulating fH and fB were signiﬁcantly
increased in subjects with AGT (195.4  63.5 vs. 175.2 
53.4 g/ml, P  0.01; and 285.9  90.5 vs. 231.95  58.8,
P  0.0001, respectively) (Table 1). Concomitant treat-
ment in subjects with type 2 diabetes did not inﬂuence
circulating fH and fB levels signiﬁcantly.
In all subjects, both circulating fH and fB were
positively associated with BMI, waist-to-hip ratio, sys-
tolic and diastolic blood pressure, fasting glucose, GHb,
log fasting triglycerides, LBP, and sTNFR2 and nega-
tively with log insulin sensitivity index and HDL choles-
terol (Fig. 1, Table 2).
Among NGT subjects, similar relationships between
circulating fH and fB with BMI, waist-to-hip ratio, and log
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subjects, these associations were strengthened. In addi-
tion, the associations of circulating fH and fB with log
fasting triglycerides (r  0.30, P  0.0001; and r  0.30,
P  0.0001, respectively), LBP (r  0.26, P  0.001; and
r  0.52, P  0.0001, respectively), log insulin sensitivity
index (r  0.40, P  0.001; and r  0.42, P  0.001,
respectively), and HDL cholesterol (r  0.23, P 
0.005; and r  0.33, P  0.0001, respectively) were
especially signiﬁcant (Table 2).
In all subjects, age (P  0.03) and log insulin sensitivity
index (P  0.01) contributed independently to 20.4% of
circulating fB variance after controlling for the effects of
waist-to-hip ratio, log fasting triglycerides, and LBP in
multiple lineal regression models. Only log insulin sensi-
tivity index (P  0.02) contributed independently to 12.2%
of circulating fH variance in the same multiple lineal
regression model.
Circulating fH and fB concentration in treated type 2
diabetic patients was not signiﬁcantly different versus
untreated type 2 diabetic patients (212.9  65.3 vs. 212.2 
79.2 g/ml, P  0.9; and 327.4  96.48 vs. 311.4  102.2
g/ml, P  0.4, respectively). The possible contribution of
each treatment in the prediction of fH and fB variance
was analyzed using multiple lineal regression models.
None of the treatments had signﬁcant effects on fH or fB
concentrations.
Complement fH and fB expression analysis in adipose
tissue. CFH gene expression was signiﬁcantly increased
in subcutaneous compared with omental adipose tissue
(0.57  0.22 vs. 0.40  0.2 relative units, P  0.004).
Inversely, CFB gene expression was increased in omental
adipose tissue (0.12  0.08 vs. 0.013  0.007 relative units,
P  0.0001). CFB gene expression in omental adipose
tissue was positively associated with BMI, fasting glucose,
and log fasting triglycerides and negatively with HDL
cholesterol; CFH gene expression in omental adipose
tissue was associated with insulin resistance (Table 3). In
fact, when we analyzed complement factor gene expres-
sion according to insulin resistance status, only CFH was
signiﬁcantly more expressed in omental adipose tissue
from insulin-resistant subjects (Table 4).
Complement fH and fB expression analysis in adipo-
cytes and SVF cells. fH and fB were expressed in both
cell fractions from omental and subcutaneous fat depots.
Again, fB gene expression was signiﬁcantly higher in
omental than subcutaneous fat depot but speciﬁcally in
cells from the SVC fraction (0.096  0.03 vs. 0.022  0.006
relative units, P  0.001). Complement CFH gene expres-
sion was increased signiﬁcantly in cells from the SVC
fraction of the subcutaneous fat depot than in cells from
the SVC fraction of the omental fat depot (0.40  0.19 vs.
0.24  0.02 relative units, P  0.04). In both fat depots, fH
gene expression was signiﬁcantly higher than complement
fB gene expression (Fig. 2). No differences between fat
depots were found regarding fH and fB gene expression in
adipocytes (Fig. 2).
Weight loss study. Characteristics of the subjects are
shown in Table 5. In this independent cohort, the associ-
TABLE 4
Complement factor expression according to insulin resistance
status
Subjects with
HOMA value
3.9
Subjects with
HOMA value
3.9 P
n 20 18
Omental CFH
expression 0.35  0.16 0.59  0.12 0.003
Omental CFB
expression 0.11  0.03 0.16  0.04 0.08
Subcutaneous CFH
expression 0.56  0.19 0.57  0.22 0.9
Subcutaneous CFB
expression 0.0137  0.08 0.0136  0.06 0.9
Data are means  SD unless otherwise indicated.
TABLE 3
Correlation between omental and subcutaneous CFB and CFH expression and selected metabolic parameters
Omental Subcutaneous
CFB expression
(n  38)
CFH expression
(n  38)
CFB expression
(n  38)
CFH expression
(n  38)
rPrPr P rP
Age (years) 0.07 0.7 0.12 0.5 0.25 0.17 0.49 0.005
BMI (kg/m
2) 0.35 0.05 0.23 0.18 0.02 0.9 0.01 0.9
Fasting glucose (mg/dl) 0.44 0.02 0.25 0.16 0.02 0.93 0.14 0.4
Fasting insulin (mU/l) 0.11 0.5 0.50 0.004 0.03 0.85 0.22 0.25
HOMA-IR 0.13 0.5 0.49 0.006 0.08 0.66 0.15 0.4
Fasting triglycerides (mg/dl) 0.48 0.02 0.02 0.9 0.04 0.87 0.2 0.37
HDL cholesterol (mg/dl) 0.63 0.002 0.34 0.1 0.07 0.7 0.02 0.9
Signiﬁcant data are shown in bold.
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FIG. 2. Study of CFH and CFB relative gene expression in SVC and
adipocytes from omental (OM) and subcutaneous (SC) fat depots.
COMPLEMENT FACTOR H AND INSULIN RESISTANCE
204 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgations of circulating fB and fH concentrations with BMI,
waist circumference, and insulin sensitivity (QUICKI in-
dex) were replicated (Fig. 3). Circulating fB and fH con-
centrations also were associated with fasting triglycerides
(r  0.33, P  0.04 for both). Weight loss led to a
signiﬁcant decrease of circulating fB and fH concentra-
tions (Fig. 4). Interestingly, the decrease in circulating fB
and fH concentrations was mainly observed in young
subjects, deﬁned as younger than the median age of the
cohort (42 years) (Fig. 4). The baseline ratio of fB to fH
was associated with weight loss: the higher the ratio, the
higher the weight loss (r  0.41; P  0.008). Again, this
association was mainly observed in young subjects (31 
8.06 years) (r  0.61; P  0.006) but not in older subjects
(56.3  7.7 years) (r  0.23; P  0.3).
In agreement with this age-discordant effects, the de-
crease in fasting triglycerides concentrations was parallel
to that of fB and fH in older subjects (r  0.48, P  0.02;
and r  0.44, P  0.04, respectively) but not in younger
subjects (r  0.26, P  0.2; and r  0.31, P  0.3,
respectively). The decrease of fH and fB after weight loss
was similar in men and women (fH in men: from 279.2 
61.6 to 249.4  75.5 relative units, P  0.06 and fB in men:
from 302.5  80.4 to 276.1  60.5 relative units, P  0.1; fH
in women: from 248.6  53.5 to 219.4  66.2 relative units,
P  0.07 and fB in women: from 306.1  71.8 to 272.3  71.1
relative units, P  0.1).
Effects of rosiglitazone administration. Subjects
treated with rosiglitazone and control subjects were sim-
ilar in sex (10 men and 2 women vs. 5 men and 3 women,
P  0.35), age (65  7.7 vs. 65.5  11.7 years, P  0.9), and
BMI (30.2  4.2 vs. 31.3  4.3 kg/m
2, P  0.5). Rosiglita-
zone led to signiﬁcantly increased insulin sensitivity (glu-
cose infusion rate during the clamp: from 46  9.5 to
TABLE 5
Subject characteristics in the weight loss study
Baseline
Post-weight
loss P
n 42 42
Age (years) 43.1  15 43.1  15
BMI (kg/m
2) 36.3  8.4 30.3  5.3 0.0001
Waist-to-hip ratio 0.95  0.08 0.93  0.07 0.01
Systolic blood pressure
(mmHg) 126.2  15.9 119.7  12.7 0.015
Diastolic blood pressure
(mmHg) 80.6  9.6 75.7  6.8 0.003
Fasting glucose (mg/dl) 95.5  10.7 90.1  7.9 0.008
Insulin (mU/l) 17.9  13.8 11.7  6.1 0.04
Total cholesterol (mg/dl) 204.4  35.8 175.6  25.3 0.001
HDL cholesterol (mg/dl) 53.4  12.4 51.5  11.7 0.23
LDL cholesterol (mg/dl) 129.02  32.9 107.9  22.9 0.0001
Log 10 fasting
triglycerides (mg/dl) 2.04  1.6 1.9  1.48 0.0001
QUICKI 0.32  0.03 0.35  0.04 0.01
HOMA-IR 4.2  3.4 2.56  1.4 0.04
fH (g/ml) 264.7  59.3 235.15  72 0.009
fB (g/ml) 304.26  75.5 274.3  67 0.025
Data are means  SD unless otherwise indicated.
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FIG. 3. Baseline linear relationships between CFH and CFB with BMI, waist circumference, and insulin sensitivity (QUICKI) in the weight loss
study.
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1  min
1, P  0.0001), whereas BMI
did not change signiﬁcantly (30.8  4.3 kg/m
2, P  0.1). In
control subjects, glucose infusion rate tended to decrease
(from 46.9  10.9 to 44  9.4 vs. mol  kg
1  min
1, P 
0.05), whereas BMI remained unchanged (31.5  4.5,
kg/m
2, P  0.3).
Circulating fH concentration decreased signiﬁcantly (by
35%; P  0.02) in parallel to increased insulin sensitivity
in subjects receiving rosiglitazone (Fig. 5B). In control
subjects, circulating fH concentration tended to increase
(from 202.7  32.1 to 228.3  28.8 g/ml, P  0.09).
Interestingly, the change in glucose infusion rate was
inversely associated with the change of circulating fH
concentrations (r  0.49; P  0.02) (Fig. 5A). Circulating
fB did not change signiﬁcantly in either group (264.9 
62.6 vs. 270.3  64.7 g/ml, P  0.5 in subjects receiving
rosiglitazone; 265.3  53.9 vs. 272.7  57.1 g/ml, P  0.7
in control subjects).
Baseline
Complement Factor H (ug/ml)
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FIG. 4. Changes in circulating CFH (A) and CFB (B) from baseline (gray lines) to after weight loss (black lines) in all subjects (left panels) and
according to age (right panels). Subjects were classiﬁed into younger and older than 42 years (median age of the cohort).
COMPLEMENT FACTOR H AND INSULIN RESISTANCE
206 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgDISCUSSION
Plasma complement proteins are mainly derived from the
liver, although other tissues can contribute signiﬁcantly
(35). The main components of the classic and alternative
complement pathways are also produced in the adipose
tissue (18–20). In 1989, adipsin, a major protein product of
mature adipocytes, was reported to be highly homologous
to fD, a serine protease whose only known function was
the cleavage of fB in the complement alternative pathway
(36). Adipsin and fD were later demonstrated to be iden-
tical, with adipose tissue being a major source of fD in vivo
and adipocytes also producing C3 and fB and activating
the alternative pathway in vitro and in vivo (20,37). Sub-
sequently, another link between the adipocyte and the
complement system was apparent with the description of
adiponectin, an adipocyte-speciﬁc product that is highly
homologous to C1q (38). To the best of our knowledge,
this is the ﬁrst report demonstrating CFH gene expression
in human adipose tissue and circulating fH levels in
association with obesity measures. CFH gene expression
has been reported in mice adipose tissue and nondifferen-
tiated adipocytes but not in association with obesity or
insulin resistance (37).
Both adipose tissue CFH gene expression and circulat-
ing fH concentration were signiﬁcantly associated with
insulin resistance and several metabolic parameters
(blood pressure, lipid parameters), mainly in AGT sub-
jects. Interestingly, the association between CFH gene
expression and insulin resistance was only found in the
omental fat depot. Improvement of insulin resistance
induced by weight loss or rosiglitazone led to decreased
circulating fH concentrations. The unchanged BMI of
subjects treated with rosiglitazone and the relationship
between the change in insulin sensitivity and circulating
fH levels suggest that insulin resistance is a driving force
in the induction of increased fH levels.
In fact, alterations in innate immunity are well known in
those with obesity and insulin resistance. Activation of the
alternative pathway of complement has been previously
reported in individuals at risk of arterial disease linked to
central fatness, including those with hypertension, type 2
diabetes, dyslipidemia, and coronary artery disease
(18,21,22). fH might function as a buffer mechanism to
counteract the activation of the alternative complement
pathway associated with increased expression of fB and
fD in obesity and insulin resistance. However, the in-
creased fH expression in adipose tissue could be caused
by a global deregulation of adipocyte-derived production
of proinﬂammatory mediators. In addition, adipocyte-rel-
evant functions of these proteins are not currently known.
The physiological role of the adipose tissue is to act as
an energy store, accumulating triglycerides in times of
plenty for use in times of need. Adipocytes express all the
components required for the local generation of C3a and
ASP/C3adesArg, which can then act to mediate this stor-
age function. Both C3a and ASP/C3adesArg have potent
activity as acylation-stimulating proteins, promoting the
esteriﬁcation of fatty acids into triglycerides, raising mem-
brane transport of glucose into adipocytes, and increasing
the activity of diacylglycerol acyltransferase. All these
effects markedly increase the rate of triglyceride synthesis
(39). fD expression is increased in fasting or catabolic
states and decreased in various models of obesity. It is
therefore possible that modulating its capacity to activate
the complement alternative pathway, the adipocyte helps
to adjust its physiology to the need for triglyceride storage
or release. We observed a cross-sectional association
between fasting triglycerides, fB, and fH concentrations in
two different cohorts. After weight loss, the decrease
in the circulating concentrations of all these factors run in
parallel but only in those subjects over the median age of
the cohort. Mean fB and fH concentrations did not change
signiﬁcantly after weight loss in this latter group, suggest-
ing that the relationship between these complement fac-
tors and triglycerides is not modiﬁable once a critical age
is reached. However, this hypothesis should be explored
more in depth.
A failure in the regulation of the alternative complement
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(14,40,41), including partial lypodistrophy. This is a rare
disease in which there is loss of fat usually from the upper
part of the body. The disease is frequently associated with
mesangiocapillary (membranoproliferative) glomerulone-
phritis type II, unbalanced local production of fB and fD,
and deﬁciencies in fH (42,43). Interestingly, we observed
that an increased baseline fB-to-fH ratio was direcly asso-
ciated with the degree of weight loss in young subjects.
Again, this observation needs to be replicated in a larger
series of subjects. Further functional studies are necessary
to test this hypothesis.
Complement is an essential part of innate immunity and
plays a central role in the elimination of microbes, clearing
of immune complexes and damaged self cells, and modu-
lating the adaptive immune response. Complement genes
are regulated by cytokines, such as interleukin-1, interleu-
kin-6, tumor necrosis factor-	 (TNF-	), or interferon-
 at
the transcriptional level (44). The chronic inﬂammatory
state associated with insulin resistance and obesity could
lead to an increased gene expression and activation of the
complement pathway. In this study, circulating fH and fB
were signiﬁcantly and positively associated with inﬂam-
matory parameters (sTNFR2 and LBP). sTNFR2 is a
known surrogate of endogenous TNF-	 action. LBP is
produced by the liver in response to bacterial endotoxin
and constitutes an endotoxemia marker (45). High-fat diet
has been recently described to raise endotoxin transloca-
tion from the gut into the bloodstream, leading to endo-
toxin-induced metabolic alterations named as metabolic
endotoxemia (46,47). Current results suggest that meta-
bolic endotoxemia could stimulate alternative comple-
ment activation in omental adipose tissue.
We here conﬁrmed the expression of fB in adipose
tissue (18,21). Its association with insulin resistance has
been less studied. Again, circulating fB concentration, as a
marker of alternative complement pathway activation,
was signiﬁcantly associated with insulin resistance and
several metabolic parameters (blood pressure, fasting
triglycerides, and HDL cholesterol, mainly in AGT sub-
jects; Table 2). Adipose tissue CFB gene expression
tended to be higher in subjects with insulin resistance
(Table 3B), and omental CFB gene expression was
signiﬁcantly associated with fasting glucose and triglyc-
erides (positively) and negatively with HDL cholesterol
(Table 3A).
The expression of fB was increased in omental com-
pared with subcutaneous adipose tissue, and the reverse
was found regarding fH. The increased expression of CFH
and CFB genes in adipose tissue was observed in the SVF
cells (composed by monocytes, ﬁbroblasts, and endothe-
lial cells). In addition, signiﬁcant gene expressions of these
factors were also found in mature adipocytes, although
without differences between fat depots. In conclusion,
increased circulating fH and fB concentration in subjects
with AGT could reﬂect the elevated SVC-induced alterna-
tive complement pathway activation in omental adipose
tissue linked to insulin resistance and metabolic distur-
bances. Further studies are necessary to evaluate the role
of fH in metabolism.
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